Decision and Details
Board of Directors (meeting held on 12 May 2026)Post-closing disclosure concerning the absorption-type merger with 株式会社エクサホームケア
The purpose was to consolidate the care-related product portfolio within the company and optimize the allocation of the business portfolio and management resources. The company also sought to centrally manage the product portfolio, improve the efficiency of development and sales structures, unify business operations, and accelerate decision-making.
No amount of the impact on financial results is stated. The company has determined that the surviving company and the disappearing company are expected to be able to perform their obligations.
| Item | Details |
|---|---|
| Matter Covered | Post-closing disclosure concerning the absorption-type merger with 株式会社エクサホームケア |
| Decision-Making Body | Board of Directors (meeting held on 12 May 2026) |
| Decision Date | 12 May 2026 |
| Implementation Date | 1 July 2026 (actual implementation date and effective date) |
| Period Covered | From 1 July 2026 onward (effective date of the merger) |
| Amount | Assets assumed: ¥272 million (approximate); liabilities assumed: ¥28 million (approximate) |
| Quantity / scale | Number of shares issued by the disappearing company: 200 shares; number of shares issued by the surviving company: 600 shares; number of employees of the disappearing company: 0 (fiscal year ended March 2026) |
| Impact on Business Performance | No amount of the impact on financial results is stated. The company has determined that the surviving company and the disappearing company are expected to be able to perform their obligations. |
| Reason | The purpose was to consolidate the care-related product portfolio within the company and optimize the allocation of the business portfolio and management resources. The company also sought to centrally manage the product portfolio, improve the efficiency of development and sales structures, unify business operations, and accelerate decision-making. |
| Governing Rule | Article 801, paragraph 1 of the Companies Act; Article 200 of the Ordinance for Enforcement of the Companies Act; Articles 784-2, 785, 787, 789, 796, paragraph 2, 797, 799 and 921 of the Companies Act |
| Related previous disclosures | “Pre-Closing Disclosure Document Concerning the Absorption-Type Merger” dated 25 May 2026; Official Gazette notice dated 29 May 2026 |
| Future plans | Registration of the change under Article 921 of the Companies Act is scheduled for 14 July 2026. |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose was to consolidate care-related products within 株式会社ExaMD, integrate the healthcare and care data platform with product development functions, centrally manage the product portfolio, unify business operations, improve the efficiency of development and sales structures, and accelerate decision-making.